Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 856985, 15 pages
http://dx.doi.org/10.1155/2011/856985
Review Article

Manipulating Protein Acetylation in Breast Cancer: A Promising Approach in Combination with Hormonal Therapies?

1IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM, U896, Université Montpellier1, CRLC Val d'Aurelle Paul Lamarque, Montpellier, 34298, France
2CRLC Claudius Regaud, 31052 Toulouse Cedex, France
3Laboratoire de Biologie Cellulaire et Hormonale, CHRU Arnaud de Villeneuve, 34090 Montpellier, France

Received 13 July 2010; Accepted 3 November 2010

Academic Editor: Minoru Yoshida

Copyright © 2011 Aurélien Linares et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group,” Lancet, pp. 1451–1467, 1998.
  2. W. L. McGuire, K. B. Horwitz, O. H. Pearson, and A. Segaloff, “Current status of estrogen and progesterone receptors in breast cancer,” Cancer, vol. 39, no. 6, pp. 2934–2947, 1977. View at Google Scholar · View at Scopus
  3. V. J. Bardou, G. Arpino, R. M. Elledge, C. K. Osborne, and G. M. Clark, “Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 1973–1979, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Massarweh and R. Schiff, “Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities,” Clinical Cancer Research, vol. 13, no. 7, pp. 1950–1954, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. R. B. Riggins, R. S. Schrecengost, M. S. Guerrero, and A. H. Bouton, “Pathways to tamoxifen resistance,” Cancer Letters, vol. 256, no. 1, pp. 1–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Hoskins, L. A. Carey, and H. L. McLeod, “CYP2D6 and tamoxifen: DNA matters in breast cancer,” Nature Reviews Cancer, vol. 9, no. 8, pp. 576–586, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Heldring, A. Pike, S. Andersson et al., “Estrogen receptors: how do they signal and what are their targets,” Physiological Reviews, vol. 87, no. 3, pp. 905–931, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. X. J. Yang and E. Seto, “HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention,” Oncogene, vol. 26, no. 37, pp. 5310–5318, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. X. J. Yang and E. Seto, “The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men,” Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 206–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Vannini, C. Volpari, P. Gallinari, P. Jones, C. Steinkühler, and S. Di Marco, “Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex,” EMBO Reports, vol. 8, no. 9, pp. 879–884, 2007. View at Publisher · View at Google Scholar
  11. A. Schuetz, J. Min, A. Allali-Hassani et al., “Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity,” Journal of Biological Chemistry, vol. 283, no. 17, pp. 11355–11363, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Ficner, “Novel structural insights into class I and II histone deacetylases,” Current Topics in Medicinal Chemistry, vol. 9, no. 3, pp. 235–240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Haberland, R. L. Montgomery, and E. N. Olson, “The many roles of histone deacetylases in development and physiology: implications for disease and therapy,” Nature Reviews Genetics, vol. 10, no. 1, pp. 32–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. O. Witt, H. E. Deubzer, T. Milde, and I. Oehme, “HDAC family: what are the cancer relevant targets?” Cancer Letters, vol. 277, no. 1, pp. 8–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Weichert, “HDAC expression and clinical prognosis in human malignancies,” Cancer Letters, vol. 280, no. 2, pp. 168–176, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. P. A. Marks and R. Breslow, “Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug,” Nature Biotechnology, vol. 25, no. 1, pp. 84–90, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Tan, S. Cang, Y. Ma, R. L. Petrillo, and D. Liu, “Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents,” Journal of Hematology and Oncology, vol. 3, article no. 5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Cang, Y. Ma, and D. Liu, “New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer,” Journal of Hematology and Oncology, vol. 2, article no. 22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Liu, S. Kuljaca, A. Tee, and G. M. Marshall, “Histone deacetylase inhibitors: multifunctional anticancer agents,” Cancer Treatment Reviews, vol. 32, no. 3, pp. 157–165, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. W. S. Xu, R. B. Parmigiani, and P. A. Marks, “Histone deacetylase inhibitors: molecular mechanisms of action,” Oncogene, vol. 26, no. 37, pp. 5541–5552, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. E. Bolden, M. J. Peart, and R. W. Johnstone, “Anticancer activities of histone deacetylase inhibitors,” Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 769–784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Minucci and P. G. Pelicci, “Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer,” Nature Reviews Cancer, vol. 6, no. 1, pp. 38–51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Balasubramanian, E. Verner, and J. J. Buggy, “Isoform-specific histone deacetylase inhibitors: the next step?” Cancer Letters, vol. 280, no. 2, pp. 211–221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Stimson and N. B. La Thangue, “Biomarkers for predicting clinical responses to HDAC inhibitors,” Cancer Letters, vol. 280, no. 2, pp. 177–183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. N. Munster, D. Marchion, S. Thomas et al., “Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker,” British Journal of Cancer, vol. 101, no. 7, pp. 1044–1050, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Ellis, Y. Pan, G. K. Smyth et al., “Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma,” Clinical Cancer Research, vol. 14, no. 14, pp. 4500–4510, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Khan, S. Fotheringham, V. Wood et al., “HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 14, pp. 6532–6537, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Suzuki, Y. Y. Chen, G. K. Scott et al., “Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression,” Clinical Cancer Research, vol. 15, no. 9, pp. 3163–3171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. C. A. Krusche, P. Wulfing, C. Kersting et al., “Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis,” Breast Cancer Research and Treatment, vol. 90, no. 1, pp. 15–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. Z. Zhang, H. Yamashita, T. Toyama et al., “Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast,” Breast Cancer Research and Treatment, vol. 94, no. 1, pp. 11–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Hu, H. M. Stern, L. Ge et al., “Genetic alterations and oncogenic pathways associated with breast cancer subtypes,” Molecular Cancer Research, vol. 7, no. 4, pp. 511–522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Sotiriou, P. Wirapati, S. Loi et al., “Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis,” Journal of the National Cancer Institute, vol. 98, no. 4, pp. 262–272, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. L. H. Saal, P. Johansson, K. Holm et al., “Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 18, pp. 7564–7569, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. A. H. Bild, G. Yao, J. T. Chang et al., “Oncogenic pathway signatures in human cancers as a guide to targeted therapies,” Nature, vol. 439, no. 7074, pp. 353–357, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Chin, S. DeVries, J. Fridlyand et al., “Genomic and transcriptional aberrations linked to breast cancer pathophysiologies,” Cancer Cell, vol. 10, no. 6, pp. 529–541, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Gruvberger, M. Ringner, Y. Chen et al., “Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns,” Cancer Research, vol. 61, no. 16, pp. 5979–5984, 2001. View at Google Scholar · View at Scopus
  37. A. V. Ivshina, J. George, O. Senko et al., “Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer,” Cancer Research, vol. 66, no. 21, pp. 10292–10301, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. A. J. Minn, G. P. Gupta, P. M. Siegel et al., “Genes that mediate breast cancer metastasis to lung,” Nature, vol. 436, no. 7050, pp. 518–524, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. M. J. Van De Vijver, Y. D. He, L. J. Van 'T Veer et al., “A gene-expression signature as a predictor of survival in breast cancer,” New England Journal of Medicine, vol. 347, no. 25, pp. 1999–2009, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Wang, J. G. M. Klijn, Y. Zhang et al., “Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer,” Lancet, vol. 365, no. 9460, pp. 671–679, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. M. West, C. Blanchette, H. Dressman et al., “Predicting the clinical status of human breast cancer by using gene expression profiles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 20, pp. 11462–11467, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Yu, K. Ganesan, L. D. Miller, and P. Tan, “A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors,” Clinical Cancer Research, vol. 12, no. 11, pp. 3288–3296, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. B. J. Boersma, M. Reimers, M. Yi et al., “A stromal gene signature associated with inflammatory breast cancer,” International Journal of Cancer, vol. 122, no. 6, pp. 1324–1332, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. I. Hedenfalk, D. Duggan, Y. Chen et al., “Gene-expression profiles in hereditary breast cancer,” New England Journal of Medicine, vol. 344, no. 8, pp. 539–548, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. X. Lu, X. Lu, Z. C. Wang, J. D. Iglehart, X. Zhang, and A. L. Richardson, “Predicting features of breast cancer with gene expression patterns,” Breast Cancer Research and Treatment, vol. 108, no. 2, pp. 191–201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. C. M. Perou, T. Sørile, M. B. Eisen et al., “Molecular portraits of human breast tumours,” Nature, vol. 406, no. 6797, pp. 747–752, 2000. View at Publisher · View at Google Scholar
  47. A. L. Richardson, Z. C. Wang, A. De Nicolo et al., “X chromosomal abnormalities in basal-like human breast cancer,” Cancer Cell, vol. 9, no. 2, pp. 121–132, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Sorlie, C. M. Perou, R. Tibshirani et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10869–10874, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. J. R. Pollack, T. Sorlie, C. M. Perou et al., “Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 20, pp. 12963–12968, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Sorlie, R. Tibshirani, J. Parker et al., “Repeated observation of breast tumor subtypes in independent gene expression data sets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8418–8423, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Desmedt, F. Piette, S. Loi et al., “Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series,” Clinical Cancer Research, vol. 13, no. 11, pp. 3207–3214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Ginestier, N. Cervera, P. Finetti et al., “Prognosis and gene expression profiling of 20q13-amplified breast cancers,” Clinical Cancer Research, vol. 12, no. 15, pp. 4533–4544, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. K. R. Hess, K. Anderson, W. F. Symmans et al., “Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4236–4244, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Huang, S. H. Cheng, H. Dressman et al., “Gene expression predictors of breast cancer outcomes,” Lancet, vol. 361, no. 9369, pp. 1590–1596, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. P. M. Haverty, J. Fridlyand, L. Li et al., “High-resolution genomic and expression analyses of copy number alterations in breast tumors,” Genes Chromosomes and Cancer, vol. 47, no. 6, pp. 530–542, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. P. K. Julka, R. T. Chacko, S. Nag et al., “A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling,” British Journal of Cancer, vol. 98, no. 8, pp. 1327–1335, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Sotiriou, S. Y. Neo, L. M. McShane et al., “Breast cancer classification and prognosis based on gene expression profiles from a population-based study,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10393–10398, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Zhao, A. Langerod, Y. Ji et al., “Different gene expression patterns in invasive lobular and ductal carcinomas of the breast,” Molecular Biology of the Cell, vol. 15, no. 6, pp. 2523–2536, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. Z. Zhang, H. Yamashita, T. Toyama et al., “HDAC6 expression is correlated with better survival in breast cancer,” Clinical Cancer Research, vol. 10, no. 20, pp. 6962–6968, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Saji, M. Kawakami, S. I. Hayashi et al., “Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer,” Oncogene, vol. 24, no. 28, pp. 4531–4539, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. S. F. Chin, A. E. Teschendorff, J. C. Marioni et al., “High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer,” Genome Biology, vol. 8, no. 10, article no. R215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Nikolsky, E. Sviridov, J. Yao et al., “Genome-wide functional synergy between amplified and mutated genes in human breast cancer,” Cancer Research, vol. 68, no. 22, pp. 9532–9540, 2008. View at Publisher · View at Google Scholar
  63. A. Inoue, N. Yoshida, Y. Omoto et al., “Development of cDNA microarray for expression profiling of estrogen-responsive genes,” Journal of Molecular Endocrinology, vol. 29, no. 2, pp. 175–192, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. S. Lee, K. H. Lim, X. Guo et al., “The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis,” Cancer Research, vol. 68, no. 18, pp. 7561–7569, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Yoshida, Y. Omoto, A. Inoue et al., “Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes,” Cancer Science, vol. 95, no. 6, pp. 496–502, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. C. L. Hanigan, M. van Engeland, A. P. De Bruine et al., “An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1,” Gastroenterology, vol. 135, no. 5, pp. 1654–1664, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Davis, C. Kennedy, Y. E. Chiew, C. L. Clarke, and A. Defazio, “Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells,” Clinical Cancer Research, vol. 6, no. 11, pp. 4334–4342, 2000. View at Google Scholar · View at Scopus
  68. D. M. Vigushin, S. Ali, P. E. Pace et al., “Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo,” Clinical Cancer Research, vol. 7, no. 4, pp. 971–976, 2001. View at Google Scholar · View at Scopus
  69. R. Margueron, V. Duong, A. Castet, and V. Cavailles, “Histone deacetylase inhibition and estrogen signalling in human breast cancer cells,” Biochemical Pharmacology, vol. 68, no. 6, pp. 1239–1246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. R. Margueron, A. Licznar, G. Lazennec, F. Vignon, and V. Cavailles, “Oestrogen receptor α increases p21/C gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells,” Journal of Endocrinology, vol. 179, no. 1, pp. 41–53, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. J. P. Alao, A. V. Stavropoulou, E. W. F. Lam, R. C. Coombes, and D. M. Vigushin, “Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells,” Molecular Cancer, vol. 5, article no. 8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Ocker and R. Schneider-Stock, “Histone deacetylase inhibitors: signalling towards p21cip1/waf1,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 7-8, pp. 1367–1374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. J. P. Alao, E. W.-F. Lam, S. Ali et al., “Histone deacetylase inhibitor trichostatin A represses estrogen receptor α-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines,” Clinical Cancer Research, vol. 10, no. 23, pp. 8094–8104, 2004. View at Publisher · View at Google Scholar
  74. V. Duong, C. Bret, L. Altucci et al., “Specific activity of class II histone deacetylases in human breast cancer cells,” Molecular Cancer Research, vol. 6, no. 12, pp. 1908–1919, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. M. De Los Santos, O. Martinez-Iglesias, and A. Aranda, “Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells,” Endocrine-Related Cancer, vol. 14, no. 4, pp. 1021–1028, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Travaglini, L. Vian, M. Billi, F. Grignani, and C. Nervi, “Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status,” International Journal of Biochemistry and Cell Biology, vol. 41, no. 1, pp. 225–234, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. L. Fuino, P. Bali, S. Wittmann et al., “Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B,” Molecular Cancer Therapeutics, vol. 2, no. 10, pp. 971–984, 2003. View at Google Scholar · View at Scopus
  78. V. Chopin, R. A. Toillon, N. Jouy, and X. Le Bourhis, “P21 is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells,” Oncogene, vol. 23, no. 1, pp. 21–29, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Bali, M. Pranpat, R. Swaby et al., “Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2,” Clinical Cancer Research, vol. 11, no. 17, pp. 6382–6389, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Sharma, J. Blum, X. Yang, N. Beaulieu, A. R. Macleod, and N. E. Davidson, “Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor α (ER) promoter upon reactivation in ER-negative human breast cancer cells,” Molecular Endocrinology, vol. 19, no. 7, pp. 1740–1751, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. X. F. Liu and M. K. Bagchi, “Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo,” Journal of Biological Chemistry, vol. 279, no. 15, pp. 15050–15058, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Biçaku, D. C. Marchion, M. L. Schmitt, and P. N. Munster, “Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling,” Cancer Research, vol. 68, no. 5, pp. 1513–1519, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Kawai, H. Li, S. Avraham, S. Jiang, and H. K. Avraham, “Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α,” International Journal of Cancer, vol. 107, no. 3, pp. 353–358, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. R. Metivier, G. Penot, M. R. Hubner et al., “Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter,” Cell, vol. 115, no. 6, pp. 751–763, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Shang and M. Brown, “Molecular determinants for the tissue specificity of SERMs,” Science, vol. 295, no. 5564, pp. 2465–2468, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Leong, J. R. Sloan, P. D. Nash, and G. L. Greene, “Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor α,” Molecular Endocrinology, vol. 19, no. 12, pp. 2930–2942, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. E. Van Rooij, J. Fielitz, L. B. Sutherland et al., “Myocyte enhancer factor 2 and class ii histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor,” Circulation Research, vol. 106, no. 1, pp. 155–165, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. K. Azuma, T. Urano, K. Horie-Inoue et al., “Association of estrogen receptor a and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells,” Cancer Research, vol. 69, no. 7, pp. 2935–2940, 2009. View at Publisher · View at Google Scholar
  89. W. Fiskus, Y. Ren, A. Mohapatra et al., “Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-α levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90,” Clinical Cancer Research, vol. 13, no. 16, pp. 4882–4890, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Malik, S. Jiang, J. P. Garee et al., “Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM,” Molecular and Cellular Biology, vol. 30, no. 2, pp. 399–412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Yao, H. Li, Y. Gu, N. E. Davidson, and Q. Zhou, “Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling,” Carcinogenesis, vol. 31, no. 3, pp. 382–387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. V. Chopin, C. Slomianny, H. Hondermarck, and X. Le Bourhis, “Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1,” Experimental Cell Research, vol. 298, no. 2, pp. 560–573, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Nakata, T. Yoshida, M. Horinaka, T. Shiraishi, M. Wakada, and T. Sakai, “Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells,” Oncogene, vol. 23, no. 37, pp. 6261–6271, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. T. R. Singh, S. Shankar, and R. K. Srivastava, “HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma,” Oncogene, vol. 24, no. 29, pp. 4609–4623, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. A. J. Frew, R. K. Lindemann, B. P. Martin et al., “Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 32, pp. 11317–11322, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Shankar, R. Davis, K. P. Singh, R. Kurzrock, D. D. Ross, and R. K. Srivastava, “Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice,” Molecular Cancer Therapeutics, vol. 8, no. 6, pp. 1596–1605, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. Hirokawa, M. Arnold, H. Nakajima, J. Zalcberg, and H. Maruta, “Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance,” Cancer Biology and Therapy, vol. 4, no. 9, pp. 956–960, 2005. View at Google Scholar · View at Scopus
  98. J. Fan, W. J. Yin, J. S. Lu et al., “ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor,” Journal of Cancer Research and Clinical Oncology, vol. 134, no. 8, pp. 883–890, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. D. Palmieri, P. R. Lockman, F. C. Thomas et al., “Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks,” Clinical Cancer Research, vol. 15, no. 19, pp. 6148–6157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. R. Margueron, V. Duong, S. Bonnet et al., “Histone deacetylase inhibition and estrogen receptor α levels modulate the transcriptional activity of partial antiestrogens,” Journal of Molecular Endocrinology, vol. 32, no. 2, pp. 583–594, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. A. DeFazio, Y. E. Chiew, C. Donoghue, C. S. L. Lee, and R. L. Sutherland, “Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines,” Journal of Biological Chemistry, vol. 267, no. 25, pp. 18008–18012, 1992. View at Google Scholar · View at Scopus
  102. G. Reid, R. Metivier, C. Y. Lin et al., “Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor α, in response to deacetylase inhibition by valproic acid and trichostatin A,” Oncogene, vol. 24, no. 31, pp. 4894–4907, 2005. View at Publisher · View at Google Scholar · View at Scopus
  103. W. Rocha, R. Sanchez, J. Deschenes et al., “Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial ishikawa cells,” Molecular Pharmacology, vol. 68, no. 6, pp. 1852–1862, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Kos, G. Reid, S. Denger, and F. Gannon, “Minireview: genomic organization of the human ERα gene promoter region,” Molecular Endocrinology, vol. 15, no. 12, pp. 2057–2063, 2001. View at Publisher · View at Google Scholar · View at Scopus
  105. P. Pryzbylkowski, O. Obajimi, and J. C. Keen, “Trichostatin A and 5 Aza-2′ deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR,” Breast Cancer Research and Treatment, vol. 111, no. 1, pp. 15–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. C. M. Klinge, “Estrogen regulation of microRNA expression,” Current Genomics, vol. 10, no. 3, pp. 169–183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. A. E. Fliss, S. Benzeno, J. Rao, and A. J. Caplan, “Control of estrogen receptor ligand binding by Hsp90,” Journal of Steroid Biochemistry and Molecular Biology, vol. 72, no. 5, pp. 223–230, 2000. View at Publisher · View at Google Scholar · View at Scopus
  108. L. Whitesell and S. L. Lindquist, “HSP90 and the chaperoning of cancer,” Nature Reviews Cancer, vol. 5, no. 10, pp. 761–772, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. X. Yi, W. Wei, S. Y. Wang, Z. Y. Du, Y. J. Xu, and X. D. Yu, “Histone deacetylase inhibitor SAHA induces ERα degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling,” Biochemical Pharmacology, vol. 75, no. 9, pp. 1697–1705, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. S. H. Kim, H. J. Kang, H. Na, and M. O. Lee, “Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein,” Breast Cancer Research, vol. 12, no. 2. article no. R22, 2010. View at Google Scholar
  111. X. Yang, A. T. Ferguson, S. J. Nass et al., “Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition,” Cancer Research, vol. 60, no. 24, pp. 6890–6894, 2000. View at Google Scholar · View at Scopus
  112. N. Fortunati, S. Bertino, L. Costantino et al., “Valproic acid restores ERα and antiestrogen sensitivity to ERα-negative breast cancer cells,” Molecular and Cellular Endocrinology, vol. 314, no. 1, pp. 17–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. X. Yang, D. L. Phillips, A. T. Ferguson, W. G. Nelson, J. G. Herman, and N. E. Davidson, “Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells,” Cancer Research, vol. 61, no. 19, pp. 7025–7029, 2001. View at Google Scholar · View at Scopus
  114. J. C. Keen, L. Yan, K. M. Mack et al., “A novel histone deacetylase inhibitor, Scriptaid, enhances expression of functional estrogen receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2-deoxycytidine,” Breast Cancer Research and Treatment, vol. 81, no. 3, pp. 177–186, 2003. View at Publisher · View at Google Scholar
  115. M. Macaluso, C. Cinti, G. Russo, A. Russo, and A. Giordano, “pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-α in breast cancer,” Oncogene, vol. 22, no. 23, pp. 3511–3517, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. G. W. Woodfield, M. J. Hitchler, Y. Chen, F. E. Domann, and R. J. Weigel, “Interaction of TFAP2C with the estrogen receptor-α promoter is controlled by chromatin structure,” Clinical Cancer Research, vol. 15, no. 11, pp. 3672–3679, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. Q. Zhou, P. Atadja, and N. E. Davidson, “Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation,” Cancer Biology and Therapy, vol. 6, no. 1, pp. 64–69, 2007. View at Google Scholar · View at Scopus
  118. Q. Zhou, P. G. Shaw, and N. E. Davidson, “Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells,” Breast Cancer Research and Treatment, vol. 117, no. 2, pp. 443–451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. O. I. W. S. Yap, G. Bhat, L. Liu, and T. O. Tollefsbol, “Epigenetic modifications of the estrogen receptor β gene in epithelial ovarian cancer cells,” Anticancer Research, vol. 29, no. 1, pp. 139–144, 2009. View at Google Scholar · View at Scopus
  120. T. J. Walton, G. Li, R. Seth, S. E. McArdle, M. C. Bishop, and R. C. Rees, “DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines,” Prostate, vol. 68, no. 2, pp. 210–222, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. E. R. Jang, S. J. Lim, E. S. Lee et al., “The histone deacetylase inhibitor trichostatin a sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen,” Oncogene, vol. 23, no. 9, pp. 1724–1736, 2004. View at Publisher · View at Google Scholar · View at Scopus
  122. V. Duong, A. Licznar, R. Margueron et al., “ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors,” Oncogene, vol. 25, no. 12, pp. 1799–1806, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. H. Faus and B. Haendler, “Post-translational modifications ofsteroid receptors,” Biomedicine and Pharmacotherapy, vol. 60, no. 9, pp. 520–528, 2006. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Fu, C. Wang, A. T. Reutens et al., “p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation,” Journal of Biological Chemistry, vol. 275, no. 27, pp. 20853–20860, 2000. View at Publisher · View at Google Scholar · View at Scopus
  125. A. L. Jacob, J. Lund, P. Martinez, and L. Hedin, “Acetylation of steroidogenic factor 1 protein regulates its transcriptional activity and recruits the coactivator GCN5,” Journal of Biological Chemistry, vol. 276, no. 40, pp. 37659–37664, 2001. View at Publisher · View at Google Scholar · View at Scopus
  126. C. Wang, M. Fu, R. H. Angeletti et al., “Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity,” Journal of Biological Chemistry, vol. 276, no. 21, pp. 18375–18383, 2001. View at Publisher · View at Google Scholar · View at Scopus
  127. Y. M. Kim, E. M. Woo, Y. T. E. Chong, D. R. Homenko, and W. L. Kraus, “Acetylation of estrogen receptor α by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor,” Molecular Endocrinology, vol. 20, no. 7, pp. 1479–1493, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. H. Chen, R. J. Lin, W. Xie, D. Wilpitz, and R. M. Evans, “Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase,” Cell, vol. 98, no. 5, pp. 675–686, 1999. View at Publisher · View at Google Scholar · View at Scopus
  129. C. Lerin, J. T. Rodgers, D. E. Kalume, S. H. Kim, A. Pandey, and P. Puigserver, “GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1α,” Cell Metabolism, vol. 3, no. 6, pp. 429–438, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. N. Vo, C. Fjeld, and R. H. Goodman, “Acetylation of nuclear hormone receptor-interacting protein RIP140 regulates binding of the transcriptional corepressor CtBP,” Molecular and Cellular Biology, vol. 21, no. 18, pp. 6181–6188, 2001. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. Qiu, Y. Zhao, M. Becker et al., “HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription,” Molecular Cell, vol. 22, no. 5, pp. 669–679, 2006. View at Publisher · View at Google Scholar · View at Scopus
  132. A. Castet, A. Boulahtouf, G. Versini et al., “Multiple domains of the receptor-interacting protein 140 contribute to transcription inhibition,” Nucleic Acids Research, vol. 32, no. 6, pp. 1957–1966, 2004. View at Publisher · View at Google Scholar
  133. M. Christian, J. M. A. Tullet, and M. G. Parker, “Characterization of four autonomous repression domains in the corepressor receptor interacting protein 140,” Journal of Biological Chemistry, vol. 279, no. 15, pp. 15645–15651, 2004. View at Publisher · View at Google Scholar · View at Scopus
  134. LI. N. Wei, M. Farooqui, and X. Hu, “Ligand-dependent formation of retinoid receptors, receptor-interacting protein 140 (RIP140), and histone deacetylase complex is mediated by a novel receptor-interacting motif of RIP140,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 16107–16112, 2001. View at Publisher · View at Google Scholar · View at Scopus
  135. J. Gobinet, S. Carascossa, V. Cavailles, F. Vignon, J. C. Nicolas, and S. Jalaguier, “SHP represses transcriptional activity via recruitment of histone deacetylases,” Biochemistry, vol. 44, no. 16, pp. 6312–6320, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. V. Kurtev, R. Margueron, K. Kroboth, E. Ogris, V. Cavailles, and C. Seiser, “Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases,” Journal of Biological Chemistry, vol. 279, no. 23, pp. 24834–24843, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. J. Li, J. Wang, J. Wang et al., “Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3,” EMBO Journal, vol. 19, no. 16, pp. 4342–4350, 2000. View at Google Scholar · View at Scopus
  138. M. G. Guenther, O. Barak, and M. A. Lazar, “The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3,” Molecular and Cellular Biology, vol. 21, no. 18, pp. 6091–6101, 2001. View at Publisher · View at Google Scholar · View at Scopus
  139. H. Li, G. K. Rajendran, N. Liu, C. Ware, B. P. Rubin, and Y. Gu, “SirT1 modulates the estrogen-insulin-like growth factor-1 signaling for postnatal development of mammary gland in mice,” Breast Cancer Research, vol. 9, no. 1, article no. R1, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. L. Hodges-Gallagher, C. D. Valentine, S. E. Bader, and P. J. Kushner, “Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells,” Breast Cancer Research and Treatment, vol. 109, no. 2, pp. 241–250, 2008. View at Publisher · View at Google Scholar
  141. S. K. Rayala, A. H. Talukder, S. Balasenthil et al., “P21-activated kinase 1 regulation of estrogen receptor-α activation involves serine 305 activation linked with serine 118 phosphorylation,” Cancer Research, vol. 66, no. 3, pp. 1694–1701, 2006. View at Publisher · View at Google Scholar · View at Scopus
  142. Q. Zhou, P. G. Shaw, and N. E. Davidson, “Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells,” Breast Cancer Research and Treatment, vol. 117, no. 2, pp. 443–451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. T. H. Luu, R. J. Morgan, L. Leong et al., “A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California cancer consortium study,” Clinical Cancer Research, vol. 14, no. 21, pp. 7138–7142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  144. C. J. Lai, R. Bao, XU. Tao et al., “CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity,” Cancer Research, vol. 70, no. 9, pp. 3647–3656, 2010. View at Publisher · View at Google Scholar · View at Scopus
  145. S. Mahboobi, S. Dove, A. Sellmer et al., “Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of Imatinib hybrides as potent Inhibitors of wild-type and mutant BCR-ABL, PDGF-Rβ, and histone deacetylases,” Journal of Medicinal Chemistry, vol. 52, no. 8, pp. 2265–2279, 2009. View at Publisher · View at Google Scholar · View at Scopus
  146. X. Cai, H. X. Zhai, J. Wang et al., “Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N- hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer,” Journal of Medicinal Chemistry, vol. 53, no. 5, pp. 2000–2009, 2010. View at Publisher · View at Google Scholar · View at Scopus